Search alternatives:
automatic » automated (Expand Search)
decrease » decreased (Expand Search), increase (Expand Search)
Showing 621 - 640 results of 662 for search '(( automatic decrease ) OR ( (((aromatic OR somatic) decrease) OR (dramatic decrease)) ))', query time: 0.44s Refine Results
  1. 621
    Table 1_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx

    Table 1_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  2. 622
    Image 2_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 2_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  3. 623
    Image 4_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 4_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  4. 624
    Image 9_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 9_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  5. 625
    Image 8_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 8_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  6. 626
    Image 7_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 7_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  7. 627
    Table 1_Schistosomiasis in Ghana from baseline to now: the impact of fifteen years of interventions.docx

    Table 1_Schistosomiasis in Ghana from baseline to now: the impact of fifteen years of interventions.docx by Joseph Opare (5437238)

    Published 2025
    “…Prevalence of schistosomiasis decreased dramatically at first impact assessment, with overall prevalence at 3.5% (95% CI 2.6–4.7) and remained low in recent surveys at 6.8% (95% CI 6.1–7.6), which represents a 67.8% reduction from baseline to current prevalence.…”
    Save to List
    Saved in:
  8. 628
    Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  9. 629
    Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx

    Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  10. 630
    Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif

    Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  11. 631
    Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  12. 632
    Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  13. 633
    Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif

    Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  14. 634
    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  15. 635
    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  16. 636
    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  17. 637
    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  18. 638
    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  19. 639
    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  20. 640
    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1

    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1 by Liaozhang Wu (8371008)

    Published 2025
    “…Mitophagy inhibitor Mdivi-1 reversed the induction of ferroptosis effects of diquat via decreased Fe2+ content and increased Ca2+ level. knockdown of METTL14 reversed the therapeutic effect of Eda on diquat-induced injury. …”
    Save to List
    Saved in:

Search Tools: